Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2

COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive...

Descripción completa

Detalles Bibliográficos
Autores principales: Parashar, Nidarshana Chaturvedi, Poddar, Jit, Chakrabarti, Sasanka, Parashar, Gaurav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417262/
https://www.ncbi.nlm.nih.gov/pubmed/32791240
http://dx.doi.org/10.1016/j.meegid.2020.104497
_version_ 1783569456458366976
author Parashar, Nidarshana Chaturvedi
Poddar, Jit
Chakrabarti, Sasanka
Parashar, Gaurav
author_facet Parashar, Nidarshana Chaturvedi
Poddar, Jit
Chakrabarti, Sasanka
Parashar, Gaurav
author_sort Parashar, Nidarshana Chaturvedi
collection PubMed
description COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive is to repurpose and test the immediate efficacy of available drugs and therapeutics against COVID-19. Through this article we propose and discuss the possibility of repurposing the available nuclease resistant RNA aptamer against the nucleocapsid protein of SARS-CoV as a potential therapeutic agent for COVID-19.
format Online
Article
Text
id pubmed-7417262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74172622020-08-11 Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2 Parashar, Nidarshana Chaturvedi Poddar, Jit Chakrabarti, Sasanka Parashar, Gaurav Infect Genet Evol Article COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive is to repurpose and test the immediate efficacy of available drugs and therapeutics against COVID-19. Through this article we propose and discuss the possibility of repurposing the available nuclease resistant RNA aptamer against the nucleocapsid protein of SARS-CoV as a potential therapeutic agent for COVID-19. Elsevier B.V. 2020-11 2020-08-11 /pmc/articles/PMC7417262/ /pubmed/32791240 http://dx.doi.org/10.1016/j.meegid.2020.104497 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Parashar, Nidarshana Chaturvedi
Poddar, Jit
Chakrabarti, Sasanka
Parashar, Gaurav
Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title_full Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title_fullStr Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title_full_unstemmed Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title_short Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
title_sort repurposing of sars-cov nucleocapsid protein specific nuclease resistant rna aptamer for therapeutics against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417262/
https://www.ncbi.nlm.nih.gov/pubmed/32791240
http://dx.doi.org/10.1016/j.meegid.2020.104497
work_keys_str_mv AT parasharnidarshanachaturvedi repurposingofsarscovnucleocapsidproteinspecificnucleaseresistantrnaaptamerfortherapeuticsagainstsarscov2
AT poddarjit repurposingofsarscovnucleocapsidproteinspecificnucleaseresistantrnaaptamerfortherapeuticsagainstsarscov2
AT chakrabartisasanka repurposingofsarscovnucleocapsidproteinspecificnucleaseresistantrnaaptamerfortherapeuticsagainstsarscov2
AT parashargaurav repurposingofsarscovnucleocapsidproteinspecificnucleaseresistantrnaaptamerfortherapeuticsagainstsarscov2

Ejemplares similares